Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Lambertini

Showing results (341-350 of 375) with videos related to

Pageof 38
Sort By:
BMJ Open|August 27, 2025
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNEAlexios Matikas, Bjørn Naume, Hans Wildiers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 TrialsBenedetta Conte, Luca Boni, Giancarlo Bisagni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registryAlessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.
JAMA Network Open|February 21, 2025
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast CancerPier Paolo Maria Berton Giachetti, Stefania Morganti, Sara Gandini, et al.
JCO Global Oncology|January 13, 2022
Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast CancerShah Zeb Khan, Luca Arecco, Cynthia Villarreal-Garza, et al.
Breast (Edinburgh, Scotland)|June 17, 2026
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world studyTal Sella, Frederieke van Duijnhoven, Hans Wildiers, et al.
Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.
Breast (Edinburgh, Scotland)|December 12, 2025
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapyAyelet Shai, Hans Wildiers, Claudio Venieri, et al.
Journal of Cancer Policy|January 14, 2026
Defining the Role and Competencies of the Medical Oncologist in Diagnostic and Therapeutic Care Pathways: Consensus Recommendations from the Italian Association of Medical Oncology (AIOM)Rossana Berardi, Francesca Rossi, Valentina Tarantino, et al.
Bioengineering (Basel, Switzerland)|November 27, 2025
Development of a Machine Learning Model for Predicting Treatment-Related Amenorrhea in Young Women with Breast CancerLong Song, Zobaida Edib, Uwe Aickelin, et al.
Pageof 38

Showing results (341-350 of 375) with videos related to

Sort By:
Pageof 38
BMJ Open|August 27, 2025
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNEAlexios Matikas, Bjørn Naume, Hans Wildiers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 TrialsBenedetta Conte, Luca Boni, Giancarlo Bisagni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registryAlessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.
JAMA Network Open|February 21, 2025
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast CancerPier Paolo Maria Berton Giachetti, Stefania Morganti, Sara Gandini, et al.
JCO Global Oncology|January 13, 2022
Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast CancerShah Zeb Khan, Luca Arecco, Cynthia Villarreal-Garza, et al.
Breast (Edinburgh, Scotland)|June 17, 2026
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world studyTal Sella, Frederieke van Duijnhoven, Hans Wildiers, et al.
Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.
Breast (Edinburgh, Scotland)|December 12, 2025
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapyAyelet Shai, Hans Wildiers, Claudio Venieri, et al.
Journal of Cancer Policy|January 14, 2026
Defining the Role and Competencies of the Medical Oncologist in Diagnostic and Therapeutic Care Pathways: Consensus Recommendations from the Italian Association of Medical Oncology (AIOM)Rossana Berardi, Francesca Rossi, Valentina Tarantino, et al.
Bioengineering (Basel, Switzerland)|November 27, 2025
Development of a Machine Learning Model for Predicting Treatment-Related Amenorrhea in Young Women with Breast CancerLong Song, Zobaida Edib, Uwe Aickelin, et al.
Pageof 38